ASLAN Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de ASLAN Pharmaceuticals disminuyan a un ritmo anual de 171.4% y 14.9% respectivamente, mientras que se espera que el BPA crezca un 4.6% por año.

Información clave

-14.9%

Tasa de crecimiento de los beneficios

4.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.0%
Tasa de crecimiento de los ingresos	-171.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	03 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Sep 14

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Jan 11

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:ASLN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	N/A	-56	N/A	N/A	1
12/31/2024	N/A	-66	N/A	N/A	2
12/31/2023	12	-44	-47	-47	N/A
9/30/2023	12	-45	N/A	N/A	N/A
6/30/2023	12	-46	-59	-59	N/A
3/31/2023	N/A	-58	N/A	N/A	N/A
12/31/2022	N/A	-51	-38	-38	N/A
9/30/2022	N/A	-46	N/A	N/A	N/A
6/30/2022	N/A	-45	-36	-36	N/A
3/31/2022	N/A	-38	N/A	N/A	N/A
12/31/2021	N/A	-31	-34	-34	N/A
9/30/2021	N/A	-28	N/A	N/A	N/A
6/30/2021	N/A	-21	-21	-21	N/A
3/31/2021	N/A	-20	N/A	N/A	N/A
12/31/2020	N/A	-16	-15	-15	N/A
9/30/2020	N/A	-40	-15	-15	N/A
6/30/2020	0	-41	-20	-20	N/A
3/31/2020	N/A	-47	-24	-24	N/A
12/31/2019	3	-47	-26	-26	N/A
9/30/2019	3	-27	-29	-29	N/A
6/30/2019	3	-34	-34	-33	N/A
3/31/2019	3	-37	-47	-36	N/A
12/31/2018	N/A	-42	-63	-39	N/A
9/30/2018	N/A	-45	-63	-40	N/A
6/30/2018	N/A	-41	-61	-38	N/A
3/31/2018	N/A	-42	-52	-40	N/A
12/31/2017	N/A	-41	-35	-35	N/A
9/30/2017	1	-33	N/A	-30	N/A
6/30/2017	12	-19	N/A	-14	N/A
3/31/2017	12	-14	N/A	-8	N/A
12/31/2016	11	-9	N/A	-6	N/A
9/30/2016	11	-7	N/A	-7	N/A
6/30/2016	0	-15	N/A	-13	N/A
3/31/2016	N/A	-15	N/A	-13	N/A
12/31/2015	N/A	-14	N/A	-11	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ASLN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ASLN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ASLN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que ASLN no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que ASLN no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ASLN se prevé que sea elevada dentro de 3 años.

ASLAN Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 8.6% to US$16.00

Price target increased to US$5.50

Price target increased to US$5.50

Price target decreased to US$5.50

Recent updates

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharmaceuticals Limited Announces New Translational Data on Eblasakimab in COPD

High number of new and inexperienced directors

New major risk - Market cap size

New minor risk - Share price stability

ASLAN Pharmaceuticals Limited Presents New Data on Eblasakimab in Atopic Dermatitis and Copd Translational Models At the 7Th Dermatology Drug Development Summit

New major risk - Negative shareholders equity

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

ASLAN Pharmaceuticals Presents New Data from Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker

New major risk - Financial position

Aslan Pharmaceuticals Limited Announces Phase 2B Treatment of Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2B Study in Atopic Dermatitis

Aslan Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab's Unique Mechanism of Action in the Treatment of Atopic Dermatitis

Price target decreased by 8.6% to US$16.00

Aslan Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

Price target increased to US$5.50

Aslan Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking E-Posters At the 51St Annual European Society for Dermatological Research Meeting

Price target increased to US$5.50

ASLAN Pharmaceuticals Limited Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Price target decreased to US$5.50

ASLAN Pharmaceuticals Limited Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

Aslan Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation At the 2022 Society for Investigative Dermatology Annual Meeting

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting

ASLAN Pharmaceuticals Limited Screens the First Patient in Its Phase 2B Dose-Ranging Clinical Study of Eblasakimab in Adults with Moderate-To-Severe Atopic Dermatitis

ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

ASLAN Pharmaceuticals Limited announced that it expects to receive SGD 45 million in funding from K2 HealthVentures

ASLAN Pharmaceuticals Appoints Dr. Kathleen Metters as Independent Director

ASLAN Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of $60 million.

ASLAN Pharmaceuticals Limited announced that it expects to receive $17.999999 million in funding from Vivo Capital, LLC, Citadel Enterprise Americas LLC

ASLAN Pharmaceuticals Announces Executive Changes

ASLAN Pharmaceuticals Limited Announces New Data from a Study Conducted by University of Liverpool, UK

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Aslan Pharmaceuticals Limited Announces Clinical Development of Aslan004

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

ASLAN Pharmaceuticals Limited Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

ASLAN Pharmaceuticals Limited(GTSM:6497) dropped from S&P Global BMI Index

ASLAN Pharmaceuticals Announces Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento